Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
about
Safety of Toll-like receptor 9 agonists: a systematic review and meta-analysis.Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cellsMetronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma ModelImmunotherapy with CpG-ODN in neoplastic meningitis: A phase I trial.Trial Watch: Experimental Toll-like receptor agonists for cancer therapyIntracerebral CpG immunotherapy with carbon nanotubes abrogates growth of subcutaneous melanomas in mice.CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma modelRe-polarizing Myeloid-derived Suppressor Cells (MDSCs) with Cationic Polymers for Cancer Immunotherapy.Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor modelsHeterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application.Toll-like receptor 9 agonists as cancer therapeutics.Stimulating natural killer cells to protect against cancer: recent developments.Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?Anti-tumour strategies aiming to target tumour-associated macrophages.Tremelimumab: a review of development to date in solid tumors.One-Shot Immunomodulatory Nanodiamond Agents for Cancer Immunotherapy.Microenvironmental Effects of Cell Death in Malignant Disease.TLR9 and TLR7 agonists mediate distinct type I IFN responses in humans and nonhuman primates in vitro and in vivo.Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma.Targeting the TLR co-receptor CD14 with TLR2-derived peptides modulates immune responses to pathogens.A bifunctional nanomodulator for boosting CpG-mediated cancer immunotherapy.Toll-Like Receptor 9 Agonists for Cancer Therapy.A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours.The revival of CpG oligonucleotide-based cancer immunotherapies.
P2860
Q33413438-A16FD1F2-5BBF-405A-A734-3A8954A5DB08Q35740077-8619F595-F73E-4AF6-B32F-653E8887C4A7Q35909751-2BA28640-AA7C-4833-B01C-CC3E3B6BBE1AQ36092885-48BE06D9-AB5A-4109-A05A-F3F55D59E752Q36194849-7AF4979D-BDBB-47AB-BA8F-6A1BA29EBC59Q36353528-B6492F38-E17A-45F7-9CFC-964CEF2FBD17Q36600960-FEA47AD1-7A96-4D23-B41E-631DC2436854Q36796146-C9C0EFB7-12A7-41E2-9947-0B6F1120D071Q36827406-E79B9262-275E-4906-8FFD-13FDCD2B8DD0Q37671216-86B78964-B647-4BBA-85C4-967AFA02416AQ37831323-A589EB51-5BE0-449A-81B1-3008D5D4AC84Q37877269-2A11A4C7-3170-48F7-89F2-F971365F6AE9Q37952804-B0EEECB8-2D9B-458A-ABE2-9FB2EEF49B87Q38056746-684A4BA8-E12D-406F-813E-CE66FF37A4A0Q38085028-3BE6479B-76DA-482B-8826-BF47EAD209A9Q38797466-7BEF39AE-EC5D-4A06-A414-D09AA3C9F786Q38936695-B5B73184-6ABD-4C3F-B9BF-69D3603B0718Q39689723-D6E0480C-4A82-403B-86B3-C9747BA64D2BQ42591459-F3CA725C-4F61-47DF-B394-E8717002CC9CQ44655068-FD0A907D-9D97-4769-ACAA-9908171E8460Q50072990-99BD1485-C25B-4263-9B75-CAEBC5962288Q50863800-9FB2C83C-0571-4C33-8015-64341584DF02Q52659459-2E667C76-ACEA-4DC2-9A4D-1766C003DCBFQ55034836-EE8D4AE7-6D5D-44FB-AA74-F49E7286BAE5
P2860
Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Randomized phase 2/3 trial of ...... ble stage III and IV melanoma.
@en
Randomized phase 2/3 trial of ...... ble stage III and IV melanoma.
@nl
type
label
Randomized phase 2/3 trial of ...... ble stage III and IV melanoma.
@en
Randomized phase 2/3 trial of ...... ble stage III and IV melanoma.
@nl
prefLabel
Randomized phase 2/3 trial of ...... ble stage III and IV melanoma.
@en
Randomized phase 2/3 trial of ...... ble stage III and IV melanoma.
@nl
P2093
P356
P1433
P1476
Randomized phase 2/3 trial of ...... ble stage III and IV melanoma.
@en
P2093
Alfons J M van den Eertwegh
Bruce Redman
Ernest Marshall
Hassan Zarour
Jeffrey S Weber
Steven O'Day
Uwe Trefzer
P2860
P304
P356
10.1002/CNCR.24473
P407
P577
2009-09-01T00:00:00Z